Keywords
Hypertension
Mineralocorticoid Receptor Antagonists
Hypokalemia
Renin-Angiotensin System
How to Cite
Abstract
Primary hyperaldosteronism is a poorly recognized but prevalent syndrome, characterized by the autonomous and independent production of aldosterone, which contributes to the genesis of arterial hypertension and cardiovascular diseases. A case of a 57-year-old woman diagnosed with arterial hypertension for 12 years is presented, treated with three antihypertensive drugs without achieving objectives and encountering hypokalemia during an episode of hypertensive emergency. Only after this event are studies indicated for primary hyperaldosteronism, which allow confirmation of bilateral secretion of aldosterone through selective adrenal vein catheterization, with excellent response to management with spironolactone. The lack of knowledge of primary care physicians about how to suspect and initiate the approach to this pathology has led to less than 1 % of real cases being diagnosed. With this case we pretend to socialize the diagnostic and therapeutic approach to this pathology.
References
Lee FT, Elaraj D. Evaluation and Management of Primary Hyperaldosteronism. Surg Clin North Am. 2019;99(4):731–745.
Fardella CE, Mosso LM, Carvajal CA. Hiperaldosteronismo primario. Rev Méd Chile. 2008;136(7):905–914.
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10-20.
Fardella CE, Carvajal CA, Mosso LM. Primary Hyperaldosteronism in the Hypertensive Disease. Curr Hypertens Rev. 2006;2(1):33–40.
Villalba NL, Rivera Martínez E, Vizcaíno JA, González NS, Medina IM, Ortega SS. Hiperaldosteronismo en una población de pacientes hipertensos. Medicina (B Aires). 2019;79(3):185–190.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916.
Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19-R29.
Liu YY, King J, Kline GA, Padwal RS, Pasieka JL, Chen G, et al. Outcomes of a Specialized Clinic on Rates of Investigation and Treatment of Primary Aldosteronism. JAMA Surg. 2021;156(6):541-549.
Vaidya A, Mulatero P, Baudrand R, Adler GK. The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocr Rev. 2018;39(6):1057-1088.
Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J Clin Endocrinol Metab. 2020;105(12):3771–3783.
Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: A controlled cross-sectional study. Hypertension. 2013;62(2):331–336.
Khokhunov OA, Karonova TL, Tsoy UA, Grineva EN. Cardiovascular complications in patients with primary hyperaldosteronism. Arter Hypertens. 2017;23(3):203–211.
Gkaniatsa E, Ekerstad E, Gavric M, Muth A, Trimpou P, Olsson DS, et al. Increasing Incidence of Primary Aldosteronism in Western Sweden during 3 Decades-Yet An Underdiagnosed Disorder. J Clin Endocrinol Metab. 2021;106(9):e3603–e3610.
Builes CA, Sierra JG. Hipertensión Secundaria Hiperaldosteronismo primario: reporte de caso. Acta Med Colomb. 2013;38(2):86–90.
Pai SG, Shivashankara KN, Pandit V, Sheshadri S. Symptomatic hypocalemia in primary hyperaldosteronism: a case report. J Korean Med Sci. 2009;24(6):1220-1223.
Sabbadin C, Fallo F. Hyperaldosteronism: Screening and Diagnostic Tests. High Blood Press Cardiovasc Prev. 2016;23(2):69–72.
Wu S, Yang J, Hu J, Song Y, He W, Yang S, et al. Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta analysis. Clin Endocrinol (Oxf). 2019;90(5):641- 648.
Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, Van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–1235.
Betz MJ, Zech CJ. Adrenal venous sampling in the diagnostic workup of primary aldosteronism. Br J Radiol. 2022;95(1129)1-8.
Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48(5):756–760.
Burgess ED, Lacourcière Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, et al. Long-Term Safety and Efficacy of the Selective Aldosterone Blocker Eplerenone in Patients with Essential Hypertension. Clin Ther. 2003;25(9):2388–2404.
Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126–148.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–59.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Médicas UIS